Versant Ventures, which incubated the cell-based immunotherapy developer based on Harvard and Stanford research, has backed a $160m round.
Century Therapeutics, a US-based immuno-oncology therapy developer based on research at Harvard and Stanford universities, completed a $160m series C round on Wednesday led by Casdin Capital.
Leaps by Bayer, the corporate venturing arm of pharmaceutical and chemical group Bayer, also contributed to the round, as did financial services and investment group Fidelity Management and Research and sovereign wealth fund Qatar Investment Authority.
Venture capital firm Versant Ventures, Avidity Partners, Federated Hermes’ Kaufmann Funds, Logos Capital and Marshall…
